New biomarkers in prostate cancer

ONCOLOGY (United States)

Volumn 28, Issue 2, 2014, Pages

  David Crawford, E ^a   Ventii, Karen ^b   Shore, Neal D ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b Atlantic Urology Clinics ^*

^c Carolina Urologic Research Center Atlantic Urology Clinics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

AWARENESS; CELL CYCLE PROGRESSION; CIRCULATING TUMOR CELL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DIGITAL RECTAL EXAMINATION; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH CARE COST; HEALTH EDUCATION; HUMAN; PRACTICE GUIDELINE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 84896341551     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100:888-97.
3. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117-23.
4. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981-90.
5. National Cancer Institute. SEER cancer statistics. Table 1.18: Lifetime risk (percent) of dying from cancer by site and race/ethnicity. Males, total U.S., 2007-2009. Available from: http://seer.cancer.gov/csr/1975_2009_pops09//results_merged/topic_lifetime_risk.pdf. Accessed January 8, 2014.
6. Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975_2010. Accessed January 8, 2014.
7. National Cancer Institute. SEER cancer statistics. Table 1.15. Lifetime risk (percent) of being diagnosed with cancer by site and race/ethnicity. Males, total U.S., 2007-2009. Available from: http://seer.cancer.gov/csr/1975_2009_pops09//results_merged/topic_lifetime_risk.pdf. Accessed January 8, 2014.
8. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116:5226-34.
9. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202-9.
10. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:419-26.
11. Barbieri CE, Bangma CH, Bjartell A, et al. The mutational landscape of prostate cancer. Eur Urol. 2013;64:567-76.
12. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470:214-20.
13. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-61.
14. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:762-71.
15. National Cancer Institute. Prostate-specific antigen (PSA) test. Available from: http://www.cancer.gov/cancertopics/factsheet/detection/PSA. Accessed January 8, 2014.
16. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-32.
17. Crawford ED, Grubb R 3rd, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011;29:355-61.
18. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-90.
19. Stephan C, Vincendeau S, Houlgatte A, et al. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem. 2013;59:306-14.
20. de la Taille A, Irani J, Graefen M, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol. 2011;185:2119-25.
21. Crawford ED, Rove KO, Trabulsi EJ, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012;188:1726-31.
22. Stewart GD, et al. Clinical utility of a multiplexed epigenetic gene assay to detect cancer in histopathologically negative prostate biopsies: results of the multicenter MATLOC study. American Urological Association annual meeting. Atlanta, GA; 2012. Abstract LBA6.
23. Trock BJ, Brotzman MJ, Mangold LA, et al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int. 2012;110:56-62.
24. Stewart GD, Van Neste L, Delvenne P, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol. 2013;189:1110-6.
25. Aubry W. Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies, reduce spending. Am Health Drug Benefits. 2013;6:15-24.
26. Robinson K, Creed J, Reguly B, et al. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis. 2013;16:398.
27. Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011;3:94ra72.
28. Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2012;pii: S0302-2838(12)01345-0.
29. Salami SS, Schmidt F, Laxman B, et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol. 2013;31:566-71.
30. Chaux A, Peskoe SB, Gonzalez-Roibon N, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol. 2012;25:1543-9.
31. Reid AH, Attard G, Ambroisine L, et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer. 2010;102:678-84.
32. Metamark Genetics. About ProMark. Available from: http://www.metamarkgenetics.com. Accessed January 16, 2014.
33. Klein E, Maddala C, Millward C, et al. Development of a needle biopsy-based genomic test to improve discrimination of clinically aggressive from indolent prostate cancer. Poster presentation at the American Society of Clinical Oncology annual meeting. Chicago, IL; 2012. Abstr 456.
34. Cooperberg M, Simko J, Falzarano S, et al. Development and validation of the biopsy-based genomic prostate score (GPS) as a predictor of high grade or extracapsular prostate cancer to improve patient selection for active surveillance. Presented at the American Urological Association annual meeting. San Diego, CA; 2013. Abstr 2131.
35. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12:245-55.
36. Ghadjar P, Zwahlen D, Aebersold DM, Zimmermann F. Postoperative radiotherapy after radical prostatectomy: indications and open questions. Prostate Cancer. 2012;2012:963417.
37. Badani K, Thompson DJ, Buerki C, et al. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget. 2013;4:600-9.
38. Karnes RJ, Bergstralh EJ, Davicioni E, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol. 2013;190:2047-53.
39. Chen CL, Mahalingam D, Osmulski P, et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate. 2013;73:813-26.
40. Halabi S, Small EJ, Hayes DF, et al. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol.2003;21:490-5.